Companies › Shanghai Cell Therapy Group
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Super DC Cell Injection dendritic cell vaccine | – | Phase 1 | Solid Tumor Cancer | Dec 2026 |
| Armored Dendritic Cell Injection Dendritic cell therapy expressing armored antibodies | – | Phase 1 | Solid Cancers | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07146672 | Super DC Cell Injection | Phase 1 | Solid Tumor Cancer | Oncology | Dec 2026 |
| NCT07479667 | Armored Dendritic Cell Injection | Phase 1 | Solid Cancers | Oncology | Dec 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.